The estimated Net Worth of Capital Iii Llc Care Capita... is at least 17.8 百万$ dollars as of 18 March 2015. Capital Capita owns over 1,206,700 units of Minerva Neurosciences Inc stock worth over 4,439,121$ and over the last 10 years Capital sold NERV stock worth over 13,326,860$.
Sign up
Capital Capita NERV stock SEC Form 4 insiders trading
Capital has made over 5 trades of the Minerva Neurosciences Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Capital sold 1,206,700 units of NERV stock worth 6,938,525$ on 18 March 2015.
The largest trade Capital's ever made was selling 1,206,700 units of Minerva Neurosciences Inc stock on 18 March 2015 worth over 6,938,525$. On average, Capital trades about 494,017 units every 42 days since 2014. As of 18 March 2015 Capital still owns at least 1,662,592 units of Minerva Neurosciences Inc stock.
You can see the complete history of Capital Capita stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Minerva Neurosciences Inc
Over the last 10 years, insiders at Minerva Neurosciences Inc have traded over 49,043,620$ worth of Minerva Neurosciences Inc stock and bought 8,182,692 units worth 47,876,311$ . The most active insiders traders include & Johnson Johnson & Johnson...、Venture Associates Iii Ltd ...、Capital Iii Llc Care Capita.... On average, Minerva Neurosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of 556,476$. The most recent stock trade was executed by Remy Luthringer on 28 April 2023, trading 27,394 units of NERV stock currently worth 105,193$.
What does Minerva Neurosciences Inc do?
minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its
What does Minerva Neurosciences Inc's logo look like?
Complete history of Capital Capita stock trades at Agile Therapeutics Inc、Minerva Neurosciences Inc
Minerva Neurosciences Inc executives and stock owners
Minerva Neurosciences Inc executives and other stock owners filed with the SEC include:
-
Michael Davidson,
Chief Medical Officer -
Devin Smith,
Senior Vice President, General Counsel -
Remy Luthringer,
Chief Executive Officer and Executive Chairman of the Board of Directors -
Geoffrey Race,
Executive Vice President, Chief Financial Officer and Chief Business Officer -
Dr. Remy Luthringer Ph.D.,
Exec. Chairman & CEO -
Frederick Ahlholm,
Senior Vice President, Chief Accounting Officer -
Dr. Rémy Luthringer,
Exec. Chairman & CEO -
Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA,
Pres -
Dr. Jay B. Saoud Ph.D.,
Consultant -
William Doyle,
Lead Independent Director -
Jan van Heek,
Independent Director -
Jeryl Hilleman,
Independent Director -
Hans Hasler,
Independent Director -
David Kupfer,
Independent Director -
Fouzia Laghrissi-Thode,
Independent Director -
William Boni,
IR Contact Officer -
Jay Saoud,
Senior Vice President, Head of Research and Development -
Joseph Reilly,
Chief Operating Officer, Senior Vice President -
Dr. Ramana Kuchibhatla Ph.D.,
Sr. VP and Head of R&D -
Dr. Michael Davidson M.D.,
Chief Medical Officer -
Joseph Reilly,
Sr. VP & COO -
Frederick W. Ahlholm CPA, CPA,
Chief Financial Officer -
William B. Boni,
VP of Investor Relations & Corp. Communications -
Marc D Beer,
Director -
Mark S. Levine,
SVP,General Counsel & Sec. -
Michele Ollier,
Director -
Venture Associates Iii Ltd ...,
-
Nico Vandervelpen,
Director -
Rubertis Francesco De,
Director -
Richard E. Russell,
President -
& Johnson Johnson & Johnson...,
-
Capital Iii Llc Care Capita...,
-
Coelho Rogerio Vivaldi,
President and CEO -
Lorenzo Pellegrini,
Director -
Geoff Race,
President -
Plc Barclays,
10% owner